KURA ONCOLOGY INC (KURA)
US50127T1097 - Common Stock
KURA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. KURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KURA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
KURA had negative earnings in the past year.
KURA had a negative operating cash flow in the past year.
KURA had negative earnings in each of the past 5 years.
In the past 5 years KURA always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -34.00%, KURA is doing good in the industry, outperforming 67.64% of the companies in the same industry.
The Return On Equity of KURA (-38.42%) is better than 76.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34% | ||
| ROE | -38.42% | ||
| ROIC | N/A |
ROA(3y)-29.4%
ROA(5y)-25.63%
ROE(3y)-32.16%
ROE(5y)-28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, KURA has more shares outstanding
Compared to 5 years ago, KURA has more shares outstanding
The debt/assets ratio for KURA is higher compared to a year ago.
2.2 Solvency
KURA has an Altman-Z score of 21.73. This indicates that KURA is financially healthy and has little risk of bankruptcy at the moment.
KURA has a Altman-Z score of 21.73. This is amongst the best in the industry. KURA outperforms 93.84% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that KURA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.02, KURA perfoms like the industry average, outperforming 42.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 21.73 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 12.26 indicates that KURA has no problem at all paying its short term obligations.
KURA's Current ratio of 12.26 is amongst the best of the industry. KURA outperforms 84.76% of its industry peers.
KURA has a Quick Ratio of 12.26. This indicates that KURA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.26, KURA belongs to the top of the industry, outperforming 84.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.26 | ||
| Quick Ratio | 12.26 |
3. Growth
3.1 Past
The earnings per share for KURA have decreased by -2.46% in the last year.
EPS 1Y (TTM)-2.46%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-12.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 15.02% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.7%
EPS Next 2Y-9.81%
EPS Next 3Y0.33%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
KURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.81%
EPS Next 3Y0.33%
5. Dividend
5.1 Amount
KURA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KURA ONCOLOGY INC
NASDAQ:KURA (4/22/2024, 7:11:52 PM)
After market: 18.19 0 (0%)18.19
+0.66 (+3.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.08B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34% | ||
| ROE | -38.42% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 12.26 | ||
| Quick Ratio | 12.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-2.46%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-13.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y